NEW YORK, March 06, 2021 (GLOBE NEWSWIRE) – WHY: Rosen Law Firm, a global investment rights law firm, announces that a class action lawsuit will be filed on behalf of the securities buyers of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “class period”). A class action lawsuit has already been filed. If you want to be the main complaint, you have to move the Court no later than April 30, 2021.
SO WHAT: If you purchased Aquestive securities during Class Time you may be entitled to compensation without incurring any costs or expenses through a contingent tax arrangement.
WHAT TO DO: To engage in Aquestive class action, visit http://www.rosenlegal.com/cases-register-2047.html or call Phillip Kim, Esq. free of charge at 866-767-3653 or email [email protected] or [email protected] for information on class activity. A class action lawsuit has already been filed. If you want to be the main complaint, you have to move the Court no later than April 30, 2021. A chief planner is a representative party acting on behalf of other class members in administering the law.
WHY: We encourage investors to choose certified advice with a history of success in management positions. Issuing companies often do not have comparable knowledge or resources. Rosen Law Firm represents investors around the globe, focusing their use in securities class actions and legalizing shareholder sub-shares. Rosen Law Firm has executed the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was ranked at No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 3 annually since 2013 and has get back hundreds of millions of dollars to investors. In 2019 alone the company received more than $ 438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as the Titan Bar of Plaintiffs. Many of the firm’s lawyers are recognized by Lawdragon and Super Lawyers.
CASE INFORMATION: According to the lawsuit, defendants during the Class Period made false and / or misleading statements and / or failed to: (1) submit data to the Buccal Libervant Film for ‘New Drug Request (Libervant) seizure management (“NDA”) showed a lower level of drug demand than for certain weight groups; (2) previously reduced the NDA Libervant licensing opportunities; (3) as a result, it was expected that the U.S. Food and Drug Administration (“FDA”) would not approve Libervant NDA in its current form; and (4) as a result, the Company’s public statements were misleading and misleading at all material times. Once the real details entered the market, the lawsuit alleges that investors suffered damage.
To engage in Aquestive class action, visit http://www.rosenlegal.com/cases-register-2047.html or call Phillip Kim, Esq. free of charge at 866-767-3653 or email [email protected] or [email protected] for information on class activity.
No classes were confirmed. Until a class is confirmed, you will not be represented by an adviser unless you book one. You can choose a consultant of your choice. You can also remain an absent class member and do nothing at this stage. An investor’s ability to share in any future improvement is not dependent on serving as a key complaint.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Lawyer advertising. Previous results do not guarantee a similar result.
——————————-
Contact information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Law Firm Rosen, PA
275 Madison Avenue, 40th floor
New York, NY 10016
Phone: (212) 686-1060
Hole free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com